HRMY — Harmony Biosciences Holdings, Inc. stock price, charts and financials

QT70Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
39.14
+0.73+1.90%
OverviewShort InterestFilings
HRMYQT70Harmony Biosciences Holdings, Inc.·NASDAQ
39.14+1.90%
TA
Loading chart...
Screen all →
SLS-8.10%$11.04BHVN-0.34%$14.61NKTR-1.52%$75.32PVLA-2.31%$154.12RAPP+2.81%$46.77URGN-0.76%$46.60NUVB-0.61%$6.55ADMA-1.79%$9.72
Snapshot
Index-P/E12.27EPS (ttm)3.13Insider Own-Shs Outstand57.89MPerf Week9.00%
Market Cap2.22BForward P/E9.20EPS next Y4.18Insider Trans0.00%Shs Float50.37MPerf Month0.52%
Enterprise Value1.83BPEG-EPS next Q-Inst Own-Short Float10.15%Perf Quarter22.25%
Income181.23MP/S2.32EPS this Y54.34%Inst Trans-Short Ratio6.01Perf Half Y5.49%
Sales959.90MP/B2.22EPS next Y9.10%ROA13.20%Short Interest5.11MPerf YTD2.65%
Book/sh-P/C6.26EPS next 5Y9.04%ROE20.06%52W High41.65 -6.02%Perf Year10.79%
Cash/sh-P/FCF6.27EPS past 3/5Y-3.01% -ROIC14.96%52W Low26.01 50.51%Perf 3Y17.97%
Dividend Est.-EV/EBITDA6.76Sales past 3/5Y25.61% 40.24%Gross Margin75.42%Volatility4.82% 4.41%Perf 5Y46.83%
Dividend TTM-EV/Sales1.90EPS Y/Y TTM-1.20%Oper. Margin24.03%ATR (14)1.56Perf 10Y-
Dividend Ex-Date-Quick Ratio3.45Sales Y/Y TTM25.59%Profit Margin18.88%RSI (14)61.36Recom2.54
Dividend Gr. 3/5Y-Current Ratio3.48EPS Q/Q-29.49%SMA207.08%Beta0.91Target Price46.20
Payout0.00%Debt/Eq0.15Sales Q/Q16.22%SMA509.61%Rel Volume1.18Prev Close38.41
Employees293LT Debt/Eq0.18EarningsNov 03SMA20015.22%Avg Volume843.20KPrice39.14
IPO DateAug 19, 2020Option/ShortYes / YesEPS/Sales Surpr.-20.83% -2.47%Net Debt/EBITDA-1.46Volume994,520Change1.90%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-05-26ReiteratedDeutsche BankHold$36 → $39
Aug-05-26ReiteratedUBSNeutral$33 → $37
Aug-05-26ReiteratedTruist SecuritiesHold$45 → $34
Aug-04-26ReiteratedOppenheimerOutperform$62 → $70
Jul-31-26ReiteratedMizuhoOutperform$50 → $51
Jun-30-26ReiteratedDeutsche BankHold$31 → $36
Feb-23-26ReiteratedDeutsche BankBuy$31
Feb-19-26ReiteratedMizuho SecuritiesOutperform$46 → $50
Feb-11-26DowngradeUBSBuy → Neutral$43 → $46
Jan-08-26ReiteratedTruist SecuritiesBuy$45
Latest News
Aug-07-26
Aug-07-2610:01AM
4 Healthcare Stocks to Watch as Defensive Demand Strengthenszacks.com
Aug-06-26
Aug-06-2611:31AM
4 Stocks Trading Near 52-Week High With More Upside Potentialzacks.com
08:05AM
Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposiumglobenewswire.com
Aug-05-26
Aug-05-2603:50PM
Harmony Biosciences: Management Raised Its Game, But The Stock Has Already Reratedseekingalpha.com
03:50PM
HRMY Q2 Earnings Beat Estimates on Strong Wakix Sales, Stock Upzacks.com
01:46PM
Here is Why Growth Investors Should Buy Harmony Biosciences (HRMY) Nowzacks.com
Aug-04-26
Aug-04-2603:20PM
Harmony Biosciences Holdings, Inc. (HRMY) Q2 2026 Earnings Call Transcriptseekingalpha.com
12:06PM
Harmony Biosciences Q2 Earnings Call Highlightsmarketbeat.com
09:51AM
Harmony Biosciences Holdings, Inc. (HRMY) Beats Q2 Earnings and Revenue Estimateszacks.com
07:30AM
Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profileglobenewswire.com
Jul-31-26
Jul-31-2601:38PM
Mizuho Maintains Outperform on Harmony Biosciences Hldgs, Raises Price Target to $51Benzinga
01:01PM
4 Value Stocks to Buy as Fed Holds Rates, Mideast Risks Risezacks.com
Jul-30-26
Jul-30-2612:41PM
HRMY or ACAD: Which Is the Better Value Stock Right Now?zacks.com
10:41AM
Should Value Investors Buy Harmony Biosciences (HRMY) Stock?zacks.com
Jul-28-26
Jul-28-2612:41PM
5 Undervalued Price-to-Book Stocks Worth Adding to Your Portfoliozacks.com
Company

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue959868715——————
Cost of Goods Sold Incl. D&A237198157——————
Gross Profit724670558——————
Selling, General and Administrative Excl. Other272272221——————
Research and Development221190146——————
Other Operating Expense
100——————
Operating Income230208191——————
Interest Expense141517——————
Unusual Expense
—————————
Non-Operating Income (Expense)252118——————
Net Income Before Taxes241215192——————
Income Taxes605646——————
Consolidated Net Income180159145——————
Net Income From Continuing Operations180159145——————
Net Income180159145——————
EPS (Recurring)3.132.762.56——————
EPS (Basic, Before Extraordinaries)3.132.762.56——————
EPS (Diluted)3.082.712.51——————
EBITDA270255233——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio12.7113.8113.71——————
Price To Sales Ratio2.372.462.74——————
Gross Margin75.5077.1978.04——————
Operating Margin23.9823.9626.71——————
Net Margin18.7718.3220.28——————
Shares Outstanding585757——————
Market Capitalization2,2702,1331,961——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$42.70$37.95$33.20$28.46$23.71● Close Price0.00M0.26M0.51M0.77M1.03MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Budur KumarCHIEF MEDICAL OFFICERMay 01 '26Option Exercise0.0018,750032,997May 18
Zaeske Adam H.CHIEF COMMERCIAL OFFICERApr 07 '26Option Exercise0.007,50007,500Apr 09
Kapadia SandipCHIEF FINANCIAL OFFICERJan 26 '26Sale37.153,746139,17124,521Jan 28
Dayno Jeffrey M.PRESIDENT, CEOJan 25 '26Option Exercise0.0013,000013,000Jan 26
Kapadia SandipCHIEF FINANCIAL OFFICERJan 25 '26Option Exercise0.004,72504,725Jan 26
Serafin AndrewCHIEF STRATEGY OFFICERJan 25 '26Option Exercise0.002,60002,600Jan 26
Budur KumarCHIEF MEDICAL OFFICERJan 25 '26Option Exercise0.002,66202,662Jan 26
Serafin AndrewCHIEF STRATEGY OFFICERJan 24 '26Option Exercise0.002,50002,500Jan 26
Budur KumarCHIEF MEDICAL OFFICERJan 24 '26Option Exercise0.002,18802,188Jan 26
Dayno Jeffrey M.PRESIDENT, CEOJan 24 '26Option Exercise0.0010,500010,500Jan 26
Kapadia SandipCHIEF FINANCIAL OFFICERJan 24 '26Option Exercise0.003,81303,813Jan 26
Kapadia SandipCHIEF FINANCIAL OFFICERJan 15 '26Sale35.9220,961752,8330Jan 20
Dayno Jeffrey M.PRESIDENT, CEODec 12 '25Sale40.115,933237,9570Dec 17
Dayno Jeffrey M.PRESIDENT, CEODec 12 '25Option Exercise8.2220,000164,40020,000Dec 17
Kapadia SandipCHIEF FINANCIAL OFFICERDec 05 '25Option Exercise29.0320,000580,60020,000Dec 09
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.